This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hoover, H. C. Articles by Hanna, M. G. Search for Related Content PubMed PubMed Citation Articles by Hoover, H. C., Jr. Articles by Hanna, M. G., Jr.

Delayed Cutaneous Hypersensitivity to Autologous Tumor Cells in Colorectal Cancer Patients Immunized with an Autologous Tumor Cell: Bacillus Calmette-Guérin Vaccine¹

Departments of Surgery and Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 [H. C. H., Jr., M. S., R. B. D.], and Litton Institute of Applied Biotechnology, Litton Bionetics, Inc., Kensington, Maryland 20895 [L. C. P., M. G. H., Jr.]

The principles and procedures of active specific immunotherapy developed from studies with the inbred guinea pig hepatocarcinoma model were used as the basis of a randomized, controlled prospective trial of active specific immunotherapy of colorectal cancer patients. The goal was to determine whether colorectal cancer patients treated with vaccines made of autologous tumor cells plus Bacillus Calmette-Guérin as adjuvant would have an increased reaction to their autologous tumor cells as measured by delayed-type cutaneous hypersensitivity (DCH) responses. Our results demonstrate that the active specific immunotherapy significantly increased the DCH responses to autologous tumor cells in 16 of 24 patients (67%). The DCH response of immunized patients to autologous normal mucosa, used as a normal tissue control, did not increase significantly. Furthermore, no significant DCH responses against autologous tumor or mucosa cells were detected in a group of nonimmunized control patients. The induced DCH responses were not correlated with other factors, such as the presence of bacteria in the cell preparation or the protein concentration of the cell preparations. The qualitative and quantitative differences in DCH responses to tumor cells and to normal mucosa cells suggest that the immunizations are targeted mainly to tumor-associated antigens with tissue-associated antigens playing a secondary role.

¹ Research sponsored in part by the National Cancer Institute, Department of Health and Human Services, under Contract N01-CO-23909 with Litton Bionetics, Inc.

² To whom requests for reprints should be addressed, at Division of Surgical Oncology, Department of Surgery, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, NY 11794.

Received 10/ 6/83. Accepted 12/15/83.

This article has been cited by other articles:

				C. Gridelli, A. Rossi, P. Maione, M. L. Ferrara, V. Castaldo, and P. C. Sacco Vaccines for the Treatment of Non-Small Cell Lung Cancer: A Renewed Anticancer Strategy Oncologist, September 1, 2009; 14(9): 909 - 920. [Abstract] [Full Text] [PDF]

				D. O'Mahony, S. Kummar, and M. E. Gutierrez Non-Small-Cell Lung Cancer Vaccine Therapy: A Concise Review J. Clin. Oncol., December 10, 2005; 23(35): 9022 - 9028. [Abstract] [Full Text] [PDF]

				A. M. Thomas, L. M. Santarsiero, E. R. Lutz, T. D. Armstrong, Y.-C. Chen, L.-Q. Huang, D. A. Laheru, M. Goggins, R. H. Hruban, and E. M. Jaffee Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients J. Exp. Med., August 2, 2004; 200(3): 297 - 306. [Abstract] [Full Text] [PDF]

				T. M. Clay, A. C. Hobeika, P. J. Mosca, H. K. Lyerly, and M. A. Morse Assays for Monitoring Cellular Immune Responses to Active Immunotherapy of Cancer Clin. Cancer Res., May 1, 2001; 7(5): 1127 - 1135. [Abstract] [Full Text]

				J. E. Harris, L. Ryan, H. C. Hoover Jr, R. K. Stuart, M. M. Oken, A. B. Benson III, E. Mansour, D. G. Haller, J. Manola, and M. G. Hanna Jr Adjuvant Active Specific Immunotherapy for Stage II and III Colon Cancer With an Autologous Tumor Cell Vaccine: Eastern Cooperative Oncology Group Study E5283 J. Clin. Oncol., January 5, 2000; 18(1): 148 - 148. [Abstract] [Full Text] [PDF]

				J. W. Simons, B. Mikhak, J.-F. Chang, A. M. DeMarzo, M. A. Carducci, M. Lim, C. E. Weber, A. A. Baccala, M. A. Goemann, S. M. Clift, et al. Induction of Immunity to Prostate Cancer Antigens: Results of a Clinical Trial of Vaccination with Irradiated Autologous Prostate Tumor Cells Engineered to Secrete Granulocyte-Macrophage Colony-stimulating Factor Using ex Vivo Gene Transfer Cancer Res., October 1, 1999; 59(20): 5160 - 5168. [Abstract] [Full Text] [PDF]

				S. Osanto Vaccine Trials for the Clinician: Prospects for Tumor Antigens Oncologist, October 1, 1997; 2(5): 284 - 299. [Abstract] [Full Text] [PDF]

				A. E. Chang, J. D. Geiger, V. K Sondak, and S. Shu Adoptive Cellular Therapy of Malignancy Arch Surg, November 1, 1993; 128(11): 1281 - 1290. [Abstract] [PDF]